All In MedTech

Device Trial Radar · NCT07539324

Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD

Clinical Impact of Drug-Coated-Balloon-based Versus Drug-Eluting-Stent-based Intervention in Patients With Multivessel Coronary Artery Disease : A Prospective, Multicenter, Active-controlled, Randomized, Single-blind, Investigator-initiated Clinical Trial

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 892 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

892

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Genoss Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Apr 20, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.

Conditions

  • Multi Vessel Coronary Artery Disease
  • Percutaneous Coronary Intervention

Interventions

  • GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)Device

    GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB's active drug coating is located on the surface of the balloon, which contains 3ug Paclitaxel per 1mm2. The drug is embedded in a physiologically harmless and degradable delivery matrix (main component: shellac and vitamin E-TPGS).

  • Contemporary Drug-Eluting Stents (DES)Device

    Contemporary drug-eluting stents (DES) with either biodegradable or non-biodegradable (durable) polymer coatings, covering all regulatory-approved, thin-strut metal platforms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Net Clinical outcome (NCO)Time frame: the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.